About Neurimmune
With its Reverse Translational Medicine™ technology platform, Neurimmune translates the genetic information obtained from white blood cells from elderly human donors into therapeutic antibodies. These antibodies can have unique pharmacological activities combined with high affinity, target selectivity, excellent pharmacodynamics and low immunogenicity.
Neurimmune discovered the anti-ATTR antibody cliramitug (formerly ALXN2220, NI006) for ATTR cardiomyopathy, the anti-SOD1 antibody AP-101 for ALS and the anti-NogoA antibody NG004 for spinal cord injury, programs being currently evaluated in clinical trials.
Quote
« Neurimmune's team of scientists and clinical experts is committed to delivering innovative therapies by focusing on science-driven discoveries.»
